Rapid Micro Biosystems (NASDAQ:RPID) Downgraded to Sell Rating by Wall Street Zen

Rapid Micro Biosystems (NASDAQ:RPID) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rapid Micro Biosystems has an average rating of “Hold” and an average target price of $8.00.

Rapid Micro Biosystems Stock Down 17.3%

RPID opened at $2.83 on Friday. Rapid Micro Biosystems has a fifty-two week low of $1.86 and a fifty-two week high of $4.94. The firm has a market capitalization of $125.43 million, a P/E ratio of -2.64 and a beta of 1.38. The company’s 50-day moving average is $3.97 and its 200 day moving average is $3.54. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95.

Rapid Micro Biosystems (NASDAQ:RPID) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative net margin of 140.30% and a negative return on equity of 86.01%. The firm had revenue of $11.28 million during the quarter, compared to analysts’ expectations of $10.93 million. Research analysts expect that Rapid Micro Biosystems will post -1.1 earnings per share for the current fiscal year.

Insider Activity at Rapid Micro Biosystems

In other news, major shareholder Longitude Capital Partners Ii, sold 49,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $3.88, for a total transaction of $190,120.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO John J. Addington Wilson sold 9,603 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total value of $41,484.96. Following the transaction, the chief operating officer owned 316,762 shares of the company’s stock, valued at $1,368,411.84. The trade was a 2.94% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 249,705 shares of company stock worth $1,021,364. Company insiders own 29.96% of the company’s stock.

Institutional Investors Weigh In On Rapid Micro Biosystems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP bought a new position in Rapid Micro Biosystems during the third quarter worth about $38,000. Fifth Lane Capital LP bought a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at approximately $51,000. American Century Companies Inc. lifted its stake in shares of Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock valued at $58,000 after buying an additional 5,341 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in Rapid Micro Biosystems in the 4th quarter worth approximately $71,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Rapid Micro Biosystems in the 4th quarter worth approximately $72,000. 52.60% of the stock is currently owned by institutional investors.

Rapid Micro Biosystems News Summary

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Record revenue and raised 2026 outlook — RPID reported Q4 revenue of $11.3M and full‑year 2025 revenue of $33.6M (both record levels) and set 2026 revenue guidance of $37.0M–$41.0M with 30–38 expected system placements, signaling ongoing commercial traction. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Large customer follow‑on orders — The company announced multi‑system orders from Samsung Biologics and expanded deployments with Amgen, validating Growth Direct adoption among big pharma/CDMOs and supporting recurring system + consumables revenue upside. GlobeNewswire: Samsung Biologics Order
• Positive Sentiment: Analyst commentary supports secular growth thesis — Independent write‑ups highlight big‑pharma adoption as a key growth driver that could expand recurring revenue (service/consumables) over time. Seeking Alpha: Big‑Pharma Adoption Driving Growth
• Neutral Sentiment: Guidance near consensus but execution risk remains — 2026 revenue midpoint is close to street expectations (~$39M) and gross margin guidance (~20%) is modest; outcomes depend on hitting system placement targets and margin improvement. Yahoo Finance: Q4 2025 Earnings Preview
• Neutral Sentiment: Earnings‑call tone mixed — Management emphasized commercial progress but flagged margin and scaling pressures, producing a balanced (not unequivocally bullish) message. TipRanks: Earnings Call Summary
• Negative Sentiment: EPS miss and continued unprofitability — Q4 EPS of ($0.28) missed consensus ($0.23), and the company remains loss‑making with negative margins and ROE, a key near‑term concern for shareholders. MarketBeat: Q4 Earnings
• Negative Sentiment: Insider selling by multiple senior executives — Recent Form 4 filings show CEO, CFO and COO sales (CFO sold 7,480 shares at ~$4.32; CEO and COO also sold), which can amplify selling pressure or raise questions about insider conviction. InsiderTrades: Insider Selling

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.